Kevin美股成长价投2019-12-31 06:31
$Orgenesis(ORGS)$ $BioLife Solutions(BLFS)$ 近几年美国细胞治疗和再生医学领域发展迅速,投入资本年增长速度超过20%,Orgs为其它公司提供研发服务。算是这波细胞治疗和再生医学淘金热潮里卖铲子的商家。所以近几年公司录的非常稳定而高速的营收增长。股价从高位大幅调整下来,已经开始修复,目...查看全文
牛唐2019-10-11 22:12
$BioLife Solutions(BLFS)$ 全部收购了SAVSU,受益于细胞疗法的火热,2019年收入指引是增长39%,毛利率是七成左右,目前股价回调的厉害,可以关注查看全文
$BioLife Solutions(BLFS)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-003761 Size: 5 KB 网页链接
$BioLife Solutions(BLFS)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-003762 Size: 5 KB 网页链接
$BioLife Solutions(BLFS)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-003763 Size: 5 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-003759 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,EVP & Chief Scientific Officer,Mathew Aby J. ,卖出,450普通股, $29.38
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,CEO,Rice Michael ,卖出,690普通股, $29.38
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,Chief Quality Officer,Foster Karen A. ,卖出,293普通股, $29.38
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,VP, Global Human Resources,Aebersold Sarah ,卖出,197普通股, $29.38
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,Chief Marketing Officer,Berard Todd ,卖出,254普通股, $29.38
$BioLife Solutions(BLFS)$ 内部交易: 2022-02-10,Chief Revenue Officer,Schulz Marcus ,卖出,167普通股, $29.38